Background: Obesity represents an important public health issue. An assessment of its costs would be useful to provide recommendations for policy and decision-making strategies. The aims of our study were to carry out a systematic review to assess the economic burden of adult obesity in terms of direct and indirect costs and to perform a quality appraisal of the analysed studies. Methods: A literature search was carried out on PubMed, Scopus and Cochrane Library to retrieve cost-of-illness (COI) analyses focused on adult (aged 18 years or more) overweight or obese people and published up to 2013. COI analyses that considered direct and indirect costs were included. Each included manuscript was independently appraised by three groups of researchers on the basis of the British Medical Journal Drummond's checklist. Results: Approximately 2044 articles were initially retrieved, and 17 were included in the current review. The included studies showed a medium-high-quality level. The available studies seemed to be heterogeneous both in terms of methodology and results reporting. However, as many studies have been conducted from the payer perspective, just direct medical costs can be considered exhaustive. As only three studies included considered also indirect costs, there is no strong evidence to give a comprehensive picture of this phenomenon also from the societal perspective. Conclusion: The review confirmed that obesity absorbs a huge amount of health-care resources. Further research is therefore needed to better understand the economic impact and to identify and promote public health strategies to tackle obesity.
Introduction
O besity represents an important public health issue, so that the World Health Organization (WHO) defines it as the 'epidemic of the 21st Century'. As reported by the Organization for Economic Cooperation and Development (OECD), from the 1980s, a significant increase in obesity rates was recorded in the majority of OECD countries. 1 Between 1980 and 2008, in USA and UK, obesity rates have more than doubled among adults. Several papers, [2] [3] [4] [5] aimed at explaining the significant obesity rise, have been published during past years, and two theories have been developed to explain the obesity rise within the developed countries: the neoclassical and the behavioural. According to the neoclassical theory by Philipson, 3 the obesity rise is mainly because of the technological progress that led to decreased physical activity, related to the increase of sedentary jobs, and to a marked decrease in food prices. According to the behavioural theory by Cutler et al. 5 , obesity rise depends on the increased caloric intake, owing to the fact that technological progress has caused a decrease in both cost of food and time spent in food preparation, by increasing mass production. On the basis of these considerations, technological change is one of the main causes of obesity growth. 3, 5 Given the significant economic and social impact related to the obesity growth, an assessment of its costs would be useful to provide recommendations for policy-and decision-making strategies. 6 According to the WHO, the cost estimates of obesity epidemic account for several billion dollars per year, with a great impact on medical expenditure, and this trend is still rising worldwide, especially among developed countries. In the USA, obesity caused an increase of almost $40 billion, through 2006, because of medical spending, of which $7 billion was absorbed by prescription drug costs. 7 In Australia, in 2005, obesity-related costs were of $1721 million, of which, direct medical costs were responsible for $1084 million and indirect costs for $637 million. 8 The aims of our study were to: (i) carry out a systematic review to assess the economic burden of adult obesity (AO) and overweight in terms of direct and indirect costs and (ii) perform a quality appraisal of the analysed studies.
Methods

Literature search
A systematic review of the AO economic impact was performed. A literature search was carried out on PubMed, Scopus and Cochrane Library databases to retrieve cost-of-illness (COI) analyses on the economic burden of AO. For a systematic search, the following algorithm was used: ('body weights and measures ' To define overweight and obesity, we referred to the body mass index (BMI). BMI is a simple index of weight-for-height that is commonly used to classify underweight, overweight and obesity in adults. It is defined as the weight in kilograms divided by the square of the height in metres (kg/m 2 ). According to the BMI, an adult is considered overweight between 25 and 29.99, and obese ! 30.
9 BMI also identifies several classes of obesity as shown in table 1. 10 Eligible studies were identified by considering the following inclusion criteria:
-Prevalence and incidence COI analyses, in English language, published from 2003 to May 2013 were taken into account;
-COI analyses focused on overweight or obese adults (as defined above: BMI ! 25) aged >18 years were considered.
COI analyses that considered the economic burden of AO were included. COI analyses are the first type of economic evaluations performed within the health-care sector, although this kind of analyses are considered partial economic evaluations, as they do not combine costs with outcomes. The main purpose of this kind of analyses is to quantify the economic burden related to a particular disease borne by both health-care sector and society in terms of health-care resources and productivity losses. 11 We included COI analyses focused on both direct and indirect costs, as obesity absorbs also a huge amount of indirect costs expressed in terms of productivity losses due to working days lost and reduced productivity at work. Direct costs refer to cost borne by the Payors (that fall into the health-care setting), on the other hand, indirect costs fall outside the health-care sector and refer to productivity losses due to illness. Direct costs, in turn, can be distinguished into two different categories: medical and non-medical. The first category consists of medical expenditures directly related to the disease in object, expressed in terms of visits to physicians, diagnostic tests, drugs and hospitalizations. The second category refers to travel cost to the physician and to health-care facilities. 12 The assessment of the eligibility of the studies, the data analysis and the interpretation of results was independently carried out by three groups of researchers (C.C., A.M.F., S.C.; C.I., M.L.S., A.M.; P.P., M.A.V., W.R.).
Articles were included by considering the following criteria:
-assessment of titles and abstracts of articles yielded by the search; -collection of the full text of potentially relevant COI analyses; -analysis of the full text with the aim to assess that the included studies matched with the inclusion criteria above reported.
Study analysis and quality appraisal
Each included manuscript was independently appraised by three groups of researchers (C.C., A.M.F., S.C.; C.I., M.L.S., A.M.; P.P., M.A.V., W.R.). Disagreements between the three teams were resolved through discussion.
To assess the AO economic impact, each study was analysed by considering both direct and indirect resources absorbed because of AO-related costs.
Quality appraisal of the COI analyses included in the current review was performed on the basis of the British Medical Journal (BMJ) Drummond's checklist, 12 commonly used to appraise the quality of economic evaluations. This checklist consists of 35 items divided into three main sections: study design (7 items), data collection (14 items) and analysis and interpretation of results (14 items). As in the current review COI analyses, which are partial economic evaluations by definition, were included, items that can be assessed just in the case of full economic evaluations were considered not appropriate ( Table 2) .
Synthesis of results
The main information was selected independently by the two teams of reviewers and summarized in a 
Results
Literature search results
In figure 1 , the literature search and the selection process are depicted. About results, of the 2044 potentially relevant articles, after removing duplicates (n = 208), 1722 studies were excluded through title screening because they did not deal with obesity (n = 897) or they were not COI analyses (n = 802) or they did not consider eligible population (n = 23). Of the 114 remaining papers, 66 were excluded through abstracts' review, as they did not fit the eligibility criteria. Among the leftover 48 studies, 31 papers were rejected because they did not meet inclusion criteria, by reviewing full texts. Finally, 17 COI analyses 7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] were deemed relevant for the current review ( figure 1 -flowchart) . The main characteristics of the included papers are reported in table 3.
Most of the studies 7, [13] [14] [15] [16] [17] [18] were conducted in the USA, one in Canada, 20 two in Brazil, 21, 22 two in Germany, 23, 24 one in Japan, 19 one in UK, 25 one in Australia, 26 one in Korea 27 and one in China. 28 With reference to the perspective, many studies 7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 25, 26, 28 were carried out from the Payer's perspective, two from both societal and Payer's perspective 23, 27 and one only from the societal perspective. 24 About the type of COI analysis, several studies were retrospective, 7, 14, 17, 18, 21, 22, [24] [25] [26] [27] [28] four prospective 15, 16, 19, 20, 23 and one crosssectional. 13 Regarding cost measures, the type of costs mostly considered were direct medical costs; three studies included also indirect costs, 23, 24, 27 and one study took into account also direct non-medical costs. 26 All of the studies considering indirect costs 23, 24, 27 followed the human capital approach to quantify productivity losses.
Quality appraisal and main results about AO economic burden are reported in the following paragraphs.
Quality appraisal
The quality of the included studies was assessed according to Drummond's checklist.
12 Table 2 depicts the results of the appraisal. In all of the studies, the research question was stated (item 1), the answer to the study question was given (item 33) and the conclusions followed from the data reported (item 34). All but one study 19 stated the economic relevance of the research question (item 2).
In 88% 7, [13] [14] [15] [16] 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] studies, limits were clearly explained in the conclusion section (item 35). Just three studies met item 14 23, 24, 27 by reporting productivity changes separately, and only nine studies described methods followed to estimate quantities and unit costs (item 17). just in two studies, 24, 27 and no study gave the reason for which costs were not discounted (item 25).
Apart from two studies, 7,15 a sensitivity analysis (item 27) was not conducted.
Direct medical costs
Bahia et al. 21 showed that annual direct medical costs owing to overweight and obesity amounted to US$2152 billion in Brazil. In particular, the main cost driver was represented by hospitalizations accounting for US $1473 billion (68.4% of total costs), followed by ambulatory procedures with a related cost of US$679 million (31.6%). According to Onwudiwe et al. 14 , annual per individual direct medical costs related to overweight, obese I and obese II/III were equal to US$3115, US $3686 and US $4386. Another study conducted in US in 2005 by Arterburn et al. 13 reported an overall per capita health-care expenditure for morbidly obese adults of US $1975 (81%) greater than normal weight adults, of US $1735 (65%) greater than overweight adults and US $1415 greater (47%) than adults with class I obesity. Daviglus et al. 15 performed a study aimed at assessing obesity costs per gender showing that severely obese men led to 84% higher costs (US $6192) compared with non-overweight ones and severely obese women 88% higher (US $5618) than non-overweight women.
Thorpe et al. 16 reported that per capita spending among obese people was 37% higher than normal weight ones. According to Finkelstein et al. 7 , the increased prevalence of obesity in the USA was responsible for almost $40 billion of increased medical spending through 2006, including $7 billion in Medicare prescription drug costs.
Another study conducted in the USA showed that the total excess of medical care expenditures was on average of $15 000 for each overweight individual and $26 000 for each obese individual. 17 Wee et al. 18 reported a mean annual health-care expenditure of $2970 among normal-weight adults, mean expenditures were $3038 for overweight adults and $4333 for obese adults. The study by Jansenn et al. showed that in Ontario the physician average costs were 427$ for males and 578$ for females in overweight adults and 475$ for males and 682$ for females in obese ones. 20 A study conducted in the UK from the National Health System (NHS) perspective highlighted overweight and obesity cost accounting for £5.1 billion. 25 The retrospective COI analysis, by Sichieri et al. 22 , aimed at highlighting the economic impact of hospitalizations in adult people (>20 years) in Brazil, showed that in 2001 overall costs of overweight and obesity were equal to 3.02% and to 5.83% of total hospitalization costs among men and women, respectively. A COI carried out in China by Zhao et al. 28 reported an amount of total medical cost because of overweight and obesity equal to 21.11 billion Yuan (RMB) (US $2.74 billion), accounting for 3.7% of national total medical costs in 2003. The rationale for choosing the alternatives programs or interventions compared is stated 17 5 The alternatives being compared are clearly described 17 6 The form of economic evaluation used is stated 17 7
The choice of form of economic evaluation is justified in relation to the question addressed 17
Data Collection 8
The sources of effectiveness estimates used are stated 17 9 The details of the design and results of effectiveness study are given (if based on a single study) 17 10
Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of effectiveness study)
The primary outcome measures for the economic evaluation are clearly stated 17 12 Methods to value health status and other benefits are stated 17 13 Details of the subjects from whom evaluations were obtained are given 17 14 Productivity changes (if included) are reported separately 3 14 15
The relevance of productivity changes to the study question is discussed 3 7 7 16
Quantities of resources are reported separately from their unit costs 5 11 2 17
Methods for the estimation of quantities and unit costs are described Each number represents the combined score across all 17 included studies. N.A., Not Available; 95% CI, 95% confidence interval.
A study conducted in Japan in 2006 highlighted that mean direct total costs were 9,8% greater among the overweight and 22,3% greater among the obese compared with normal weight people. 19 
Direct medical and non-medical costs
Colagiuri et al. 26 reported that in Australia in 2005 total direct cost due to overweight and obesity was $18.8 billion. In particular, overweight accounted for $10.5 billion ($7.8 billion direct medical and $2.7 billion direct non-medical) and obesity for $8.3 billion ($6.6 billion direct medical and $1.7 billion direct non-medical).
Direct costs and indirect costs
A retrospective COI analysis by Kang et al. 27 in 2011 estimated direct costs of overweight and obesity in Korea equal to U$1081 million (men: U$497 million, women: U$584 million) and indirect costs equal to $U$706 million (men: U$527 million, women: U$178 million).
A prospective COI analysis, conducted by Wolfenstetter in Germany, 23 showed that the predicted average adjusted total direct costs per year were of E1029 for healthy weight people, E1093 for overweight and E1040 obese people. Furthermore, an overweight patient was estimated to cause higher indirect costs (E2474) compared with healthy weight people (E2136).
Another study, carried out in Germany, 24 estimated both direct and indirect costs of morbidity and mortality attributable to obesity and overweight in Germany for the year 2002. Authors quantified obesity-related costs of E4854 million in terms of direct costs and E5019 million in terms of indirect costs.
Limitations of the included studies
Six studies 7, 13, 14, 18, 20, 21 used a self-reported height and weight for prevalence of obesity, which could have brought to bias and underestimation.
In nine studies, 7, 14, 15, 21, 22, 24, 25, 27, 28 the obesity-expenditure relationship may have been confounded by unmeasured comorbidities or obesity complications.
In seven studies, 7, 14, 15, 18, 22, 23, 26 the data considered for the analysis accounted for specific samples of population (e.g. Medicare beneficiaries, specific nationality or race, etc.), which could have brought to results not really representative of the whole population of a country.
All but three studies 23, 24, 27 did not consider indirect costs in their analysis. Moreover, Jansenn 20 only included physician costs which, within Canada, only represent 13.9% of direct medical care expenditures and 7.3% of total (direct + indirect) health-care costs.
Discussion
Given the significant increase in the obesity rates recorded during the past 30 years, especially in the developed countries, 1 overweight and obesity represent a priority public health issue. 2 On the one hand, particular attention has been paid on this phenomenon by policy-and decision-makers, on the other hand, several attempts were made by researchers to investigate the obesity epidemic, analysing its causes and consequences. In particular, the neoclassical and the behavioural theories by Philipson and Cutler, aforementioned, converge to technological progress as one of the main causes of obesity growth, because of the consequent decreased physical activity and the increased caloric intake, thus emphasizing the role of lifestyle factors. 3, 5 The last played an important role in raising obesity and, consequently, the risk of developing comorbidities. 29 The concepts behind these theories represent the pillar of public health strategies aimed at reducing the epidemiological and economic burden related to obesity. With reference to the latter, the aim of this review was to address the AO and overweight both in terms of direct and indirect costs and to provide a quality appraisal of the reviewed studies.
This represents the first systematic review on adult obese and overweight people that matches both systematic search and quality appraisal of literature on the basis of Drummond and Jefferson BMJ referee checklist. 12 We previously published a similar paper, but focused on a childhood population. 30 Although several potentially relevant articles have been identified, just 17 studies met the inclusion criteria of the current systematic review, of which the majority have been carried out in the USA, where the obesity epidemic represents a huge problem to deal with. On the whole, AO absorbs a significant amount of healthcare resources. However, as many studies have been carried out from the payer perspective, just direct medical cost estimates can be considered exhaustive. In fact, only three studies included also indirect costs. 23, 24, 27 Therefore, strong evidence is not available to give a comprehensive picture of this phenomenon and, to reliably quantify AO social impact, further studies focused on indirect costs are needed, also considering that the last are estimated by Konnopka et al to be higher than direct ones. 24 The studies included in the current review show that obesity costs are higher than overweight costs, apart from the study by Wolfenstetter 23 showing that average annual direct costs were slightly higher in the case of overweight rather than in the obese group (E1093 for overweight and E1040 obese people). However, these data are justified by an intrinsic study limitation, as also reported by authors.
With reference to the quality of included studies, our results show a medium-high-quality level mainly depending on the lack of sensitivity analyses and of the productivity loss estimates (indirect costs) in almost all studies.
The studies included in the current review show that obesity and overweight are responsible for a significant economic burden from both Payors' and societal perspectives. The results of our review show that it would be useful to prevent obesity among people to save a significant amount of resources. COI analyses, by providing a picture of the magnitude of a particular phenomenon, are useful in supporting evidence-based policies for decision makers. However, a significant limit related to COI analyses is represented by the fact that they do not include also outcome measures (as full economic evaluation) and do not provide any information regarding alternative programmes. Hence COI analyses cannot support the allocation of health-care resources among alternative projects. Figure 1 Process of study selection
11,12
The results of this review could be affected by some limitations. The first one is represented by the fact that the studies included do not assess the long-term effects related to obesity, which should be analysed to have a more detailed picture of the obesity epidemic. The second limitation may be related to a potential publication bias because of the relatively small number of published COI studies in this field. Moreover, only three of 17 studies assessed both direct and indirect costs giving a more comprehensive assessment of the AO economic burden. Third, COI studies do not try to explain the rise in obesity rates. Finally, the lack of sensitivity analysis in most of the studies represents another limitation as, to give strong recommendations, the robustness of base case results should be investigated.
On the basis of the above reported considerations, it would be necessary to promote further research in this field with the aim to increase commitment and awareness among the community. To this purpose, further COI analyses should be conducted, aimed at assessing also indirect costs, as they play an important role in terms of economic burden. In fact, the productivity loss owing to obesity and obesity-related diseases should be investigated to have a more comprehensive view of the whole phenomenon. Moreover, sensitivity analyses should be carried out together with COI studies to assess the robustness of the base case results. Finally, a wider time horizon should be considered to allow taking into account all the consequences related to the obesity epidemic.
In addition, stronger evidence on the economic burden of AO could support policy-and decision-makers in intensifying public health strategies aimed to promote positive lifestyles and behaviours and planning and providing appropriate and targeted services.
In conclusion, further research is needed to better understand the AO economic impact and to identify and promote public health strategies to tackle obesity.
